NCT07787208

RecruitingPhase 1

A Study of ONO-7429 in Participants With Unresectable Advanc...

Ono Pharmaceutical Co., Ltd.Source

Ono Pharmaceutical Co., Ltd.

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

ONO-7429-01

Study Type

interventional

Estimated enrollment

80

Locations

1 country

Sites

10

Timeline

Study Start

June 19, 2026

Actual (reported)

Primary Completion

July 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

March 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 80 participants
Study completion date: March 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 10 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 19, 2026
Actual (reported)
First Submitted
August 18, 2026
Actual (reported)
First Posted
August 26, 2026
Actual (reported)
Primary Completion
July 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 26, 2026
Status Verified: August 2026
Last Update Submitted: August 24, 2026

Conditions

Solid Tumors

Outcome Measures

Primary Outcomes (2)

Dose-limiting toxicities（DLT）
From first dose through completion of the DLT evaluation period (approximately 21 days)
Adverse event (AE)
Approximately 6 months

Secondary Outcomes (16)

Area under the Plasma Concentration versus Time Curve (AUC)
Approximately 6 months
Cmax
Approximately 6 months
Tmax
Approximately 6 months
Terminal elimination half-life（T1/2）
Approximately 6 months
Ctrough
Approximately 6 months
+11 more secondary outcomes

Study Arms (1)

ONO-7429

EXPERIMENTAL

Drug: ONO-7429

Interventions

ONO-7429Drug

Specified dose on specified days

ONO-7429

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.
Participants who are refractory or intolerant to standard therapy.

Sponsors & Collaborators

Ono Pharmaceutical Co., Ltd.
Industrylead

Study Sites (10)

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

RECRUITING

Gunma University Hospital

Maebashi, Gunma, Japan

RECRUITING

Niigata Cancer Center Hospital

Niigata, Niigata, Japan

RECRUITING

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Study Officials

Project Leader
Ono Pharmaceutical Co., Ltd.
STUDY DIRECTOR

Central Study Contacts

North America Clinical Trial Support Desk

CONTACT

+18665877745(Toll-Free)clinical_trial@ono-pharma.com

International Clinical Trial Support Desk

CONTACT

+17162141777(Standard)

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 18, 2026

First Posted

August 26, 2026

Study Start

June 19, 2026

Actual (reported)

Primary Completion

July 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

NCT07902804

A Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

Phase 1Not Yet Recruiting

NCT07834359

A Study of HS-20197 in Participants With Advanced Solid Tumors

Phase 1Not Yet Recruiting

NCT07800936

HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors

Phase 1Recruiting

NCT03444701

A Study of E7130 in Participants With Solid Tumors

Phase 1Terminated

NCT07591155

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1Recruiting

NCT07274085

A Phase 1 Study of HDM2017 in Advanced Solid Tumors

Phase 1Recruiting

Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.

Participants with tumor tissue samples available for biomarker testing.

You may not qualify if:

Participants with a history or presence of severe hypersensitivity to any other antibody agents.
Participants with pericardial fluid, pleural effusion or ascites requiring treatment
Participants with uncontrolled tumor-related pain
Participants with severe peritoneal dissemination.
Participants with multiple primary cancers.
Participants with a history or presence of ILD or pulmonary fibrosis.

Contact the study team to confirm eligibility.

RECRUITING

Osaka International Cancer Institute

Osaka, Osaka, Japan

RECRUITING

Kindai University Hospital

Sakai, Osaka, Japan

RECRUITING

Saitama Medical University International Medical Center

Hidaka, Saitama, Japan

RECRUITING

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

RECRUITING

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

RECRUITING

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

RECRUITING

clinical_trial@ono-pharma.com

Study Completion

March 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 26, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07787208
Data provider: ClinicalTrials.gov
Source updated: 2026-08-26
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:29 UTC

Locations

JP(10)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (16)

Study Arms (1)

ONO-7429

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (10)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations